Market revenue in 2023 | USD 503.1 million |
Market revenue in 2030 | USD 819.7 million |
Growth rate | 7.2% (CAGR from 2023 to 2030) |
Largest segment | Molecular diagnostics |
Fastest growing segment | Immunoassays |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Immunoassays, Hematology and Coagulation, Molecular Diagnostics, Microbiology, Clinical Chemistry, Histology/Cytology, Flow Cytometry, Mass Spectroscopy |
Key market players worldwide | Quest Diagnostics Inc, 23andMe Holding Co Class A, Abbott Laboratories, Guardant Health Inc, NeoGenomics, Siemens Healthineers AG ADR, Qiagen NV, Illumina Inc, Roche Holding AG ADR |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to laboratory developed tests market will help companies and investors design strategic landscapes.
Molecular diagnostics was the largest segment with a revenue share of 24.03% in 2023. Horizon Databook has segmented the Australia laboratory developed tests market based on immunoassays, hematology and coagulation, molecular diagnostics, microbiology, clinical chemistry, histology/cytology, flow cytometry, mass spectroscopy covering the revenue growth of each sub-segment from 2018 to 2030.
The Australia LDTs market is expected to grow significantly due to research collaborations and favorable government initiatives. In December 2022, Alliance Pharma announced expanding its laboratory facility in Australia, which would further support clinical and preclinical testing.
Increasing prevalence of infectious diseases and growing geriatric population are expected to drive Australia’s LDT market. According to the Australian Institute of Health and Welfare, in 2022, cancer contributed to the greatest disease burden in the country at 17%, followed by cardiovascular diseases and others.
In addition, strategic initiatives by local players, such as new product launches, are expected to boost the market. For instance, in April 2020, BGI entered into a partnership with Minderoo to introduce Huo-Yan Laboratory Solution and expand Australia’s COVID-19 testing by an added 54,000 tests per day.
Horizon Databook provides a detailed overview of country-level data and insights on the Australia laboratory developed tests market , including forecasts for subscribers. This country databook contains high-level insights into Australia laboratory developed tests market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account